mCRPC

  • December 3, 2020  

    Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate Cancer Bookmark

    George Lundberg, MD

    A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.

    .

  • September 9, 2020  

    What’s New in Treatment for Castrate-Resistant Prostate Cancer?

    Emma Shtivelman, PhD

    About 10% to 20% of all prostate cancers are classified as castrate-resistant prostate cancer (CRPC). CRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called androgens (such as testosterone) that fuel the cancer’s growth. Most CRPCs are diagnosed as metastatic (mCRPC), meaning they have already spread beyond the prostate;… Read more »

  • June 11, 2018  

    Abiraterone May Be More Effective in Black Men With Prostate Cancer Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “Black men with metastatic castration-resistant prostate cancer (CRPC) who received hormonal therapy with the adrenal inhibitor abiraterone had greater and longer-lasting responses compared with white men, according to the results of a late-breaking study (abstract LBA5009) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago June 1–5.

    “The prospective study found that black men were more likely to have a decline in prostate-specific antigen (PSA) and had a longer median time to PSA worsening than white men. The findings were presented by Daniel George, MD, professor of medicine and surgery at Duke University.”

    Go to full article published by Cancer Network on Jun 2, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.